poisar

Stocks · News reference

Wells Fargo Maintains Overweight on MSCI, Lowers Price Target to $690

Benzinga Newsdesk

Wells Fargo analyst Jason Haas maintains MSCI (NYSE:MSCI) with a Overweight and lowers the price target from $700 to $690.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

MSCI
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Erin Kennedy

    CME vs. Morningstar: Which Financial Stock Is a Better Buy in 2026?

    CME Group and Morningstar are compared as financial infrastructure plays. CME dominates derivatives trading with an impressive 62% net margin and $6.5B revenue, but trades at a premium valuation (forward P/E 22.5). Morningstar offers investment research with lower margins (15.3%) but more attractive valuation (forward P/E 15.5). The author leans toward CME despite valuation concerns due to its superior profitability and dividend, though both stocks have underperformed the S&P 500 over longer periods.

    CMEMORNICECBOEMSCI
  3. SEC EDGAR

    8-K filing — MSCI Inc. (MSCI)

    Filed: 2026-08-07 AccNo: 0001408198-26-000049 Size: 144 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

    MSCI